Cargando…

Pathway-based dissection of the genomic heterogeneity of cancer hallmarks’ acquisition with SLAPenrich

Cancer hallmarks are evolutionary traits required by a tumour to develop. While extensively characterised, the way these traits are achieved through the accumulation of somatic mutations in key biological pathways is not fully understood. To shed light on this subject, we characterised the landscape...

Descripción completa

Detalles Bibliográficos
Autores principales: Iorio, Francesco, Garcia-Alonso, Luz, Brammeld, Jonathan S., Martincorena, Iňigo, Wille, David R., McDermott, Ultan, Saez-Rodriguez, Julio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5928049/
https://www.ncbi.nlm.nih.gov/pubmed/29713020
http://dx.doi.org/10.1038/s41598-018-25076-6
_version_ 1783319160067981312
author Iorio, Francesco
Garcia-Alonso, Luz
Brammeld, Jonathan S.
Martincorena, Iňigo
Wille, David R.
McDermott, Ultan
Saez-Rodriguez, Julio
author_facet Iorio, Francesco
Garcia-Alonso, Luz
Brammeld, Jonathan S.
Martincorena, Iňigo
Wille, David R.
McDermott, Ultan
Saez-Rodriguez, Julio
author_sort Iorio, Francesco
collection PubMed
description Cancer hallmarks are evolutionary traits required by a tumour to develop. While extensively characterised, the way these traits are achieved through the accumulation of somatic mutations in key biological pathways is not fully understood. To shed light on this subject, we characterised the landscape of pathway alterations associated with somatic mutations observed in 4,415 patients across ten cancer types, using 374 orthogonal pathway gene-sets mapped onto canonical cancer hallmarks. Towards this end, we developed SLAPenrich: a computational method based on population-level statistics, freely available as an open source R package. Assembling the identified pathway alterations into sets of hallmark signatures allowed us to connect somatic mutations to clinically interpretable cancer mechanisms. Further, we explored the heterogeneity of these signatures, in terms of ratio of altered pathways associated with each individual hallmark, assuming that this is reflective of the extent of selective advantage provided to the cancer type under consideration. Our analysis revealed the predominance of certain hallmarks in specific cancer types, thus suggesting different evolutionary trajectories across cancer lineages. Finally, although many pathway alteration enrichments are guided by somatic mutations in frequently altered high-confidence cancer genes, excluding these driver mutations preserves the hallmark heterogeneity signatures, thus the detected hallmarks’ predominance across cancer types. As a consequence, we propose the hallmark signatures as a ground truth to characterise tails of infrequent genomic alterations and identify potential novel cancer driver genes and networks.
format Online
Article
Text
id pubmed-5928049
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-59280492018-05-07 Pathway-based dissection of the genomic heterogeneity of cancer hallmarks’ acquisition with SLAPenrich Iorio, Francesco Garcia-Alonso, Luz Brammeld, Jonathan S. Martincorena, Iňigo Wille, David R. McDermott, Ultan Saez-Rodriguez, Julio Sci Rep Article Cancer hallmarks are evolutionary traits required by a tumour to develop. While extensively characterised, the way these traits are achieved through the accumulation of somatic mutations in key biological pathways is not fully understood. To shed light on this subject, we characterised the landscape of pathway alterations associated with somatic mutations observed in 4,415 patients across ten cancer types, using 374 orthogonal pathway gene-sets mapped onto canonical cancer hallmarks. Towards this end, we developed SLAPenrich: a computational method based on population-level statistics, freely available as an open source R package. Assembling the identified pathway alterations into sets of hallmark signatures allowed us to connect somatic mutations to clinically interpretable cancer mechanisms. Further, we explored the heterogeneity of these signatures, in terms of ratio of altered pathways associated with each individual hallmark, assuming that this is reflective of the extent of selective advantage provided to the cancer type under consideration. Our analysis revealed the predominance of certain hallmarks in specific cancer types, thus suggesting different evolutionary trajectories across cancer lineages. Finally, although many pathway alteration enrichments are guided by somatic mutations in frequently altered high-confidence cancer genes, excluding these driver mutations preserves the hallmark heterogeneity signatures, thus the detected hallmarks’ predominance across cancer types. As a consequence, we propose the hallmark signatures as a ground truth to characterise tails of infrequent genomic alterations and identify potential novel cancer driver genes and networks. Nature Publishing Group UK 2018-04-30 /pmc/articles/PMC5928049/ /pubmed/29713020 http://dx.doi.org/10.1038/s41598-018-25076-6 Text en © The Author(s) 2018 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
spellingShingle Article
Iorio, Francesco
Garcia-Alonso, Luz
Brammeld, Jonathan S.
Martincorena, Iňigo
Wille, David R.
McDermott, Ultan
Saez-Rodriguez, Julio
Pathway-based dissection of the genomic heterogeneity of cancer hallmarks’ acquisition with SLAPenrich
title Pathway-based dissection of the genomic heterogeneity of cancer hallmarks’ acquisition with SLAPenrich
title_full Pathway-based dissection of the genomic heterogeneity of cancer hallmarks’ acquisition with SLAPenrich
title_fullStr Pathway-based dissection of the genomic heterogeneity of cancer hallmarks’ acquisition with SLAPenrich
title_full_unstemmed Pathway-based dissection of the genomic heterogeneity of cancer hallmarks’ acquisition with SLAPenrich
title_short Pathway-based dissection of the genomic heterogeneity of cancer hallmarks’ acquisition with SLAPenrich
title_sort pathway-based dissection of the genomic heterogeneity of cancer hallmarks’ acquisition with slapenrich
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5928049/
https://www.ncbi.nlm.nih.gov/pubmed/29713020
http://dx.doi.org/10.1038/s41598-018-25076-6
work_keys_str_mv AT ioriofrancesco pathwaybaseddissectionofthegenomicheterogeneityofcancerhallmarksacquisitionwithslapenrich
AT garciaalonsoluz pathwaybaseddissectionofthegenomicheterogeneityofcancerhallmarksacquisitionwithslapenrich
AT brammeldjonathans pathwaybaseddissectionofthegenomicheterogeneityofcancerhallmarksacquisitionwithslapenrich
AT martincorenainigo pathwaybaseddissectionofthegenomicheterogeneityofcancerhallmarksacquisitionwithslapenrich
AT willedavidr pathwaybaseddissectionofthegenomicheterogeneityofcancerhallmarksacquisitionwithslapenrich
AT mcdermottultan pathwaybaseddissectionofthegenomicheterogeneityofcancerhallmarksacquisitionwithslapenrich
AT saezrodriguezjulio pathwaybaseddissectionofthegenomicheterogeneityofcancerhallmarksacquisitionwithslapenrich